Vincerx Pharma is a clinical-stage biopharmaceutical company focused on utilizing its development and oncology capabilities to develop therapies intended to address unmet medical needs for the treatment of cancer. Co.'s pipeline consists of enitociclib and a proprietary modular bioconjugation platform, which includes a small molecule drug-conjugate, VIP236 and preclinical antibody drug-conjugates, VIP943 and VIP924. Co. had been granted an exclusive, royalty-bearing, worldwide license under certain Bayer AG patents and know-how to develop, use, manufacture, commercialize, sublicense, and distribute multiple clinical and preclinical stage compounds. The VINC stock yearly return is shown above.
The yearly return on the VINC stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the VINC annual return calculation with any dividends reinvested as applicable (on ex-dates).
|